CytomX Therapeutics price to sales ratio CTMX

Market value divided by revenue over the last twelve months, since 2016.

Today, Oct 23, 2026: 27.6×
10-year median: 5.0×
Against its 10-year history: 93rd; percentile: 0 is its lowest day, 100 its highest
10-year range: 0.3× to 45.6×
Peer median: 1.5×

CytomX Therapeutics' price to sales ratio is 27.6× as of Oct 23, 2026.

That is above its ten-year median of 5.0×, higher than on 93% of days in the last ten years.

Over that time it ranged from 0.3× in Apr 2025 to 45.6× in Oct 2016.

The median for 10 large drugmakers of a similar size is 1.5×.

Price to sales ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	27.6×	6.3×	44.2×
2025	6.5×	0.3×	6.5×
2024	0.7×	0.6×	3.0×
2023	1.1×	0.8×	2.6×
2022	1.5×	1.1×	4.3×
2021	4.3×	3.3×	8.3×
2020	3.3×	3.3×	8.9×
2019	6.4×	4.0×	11.4×
2018	9.0×	7.7×	25.1×
2017	16.0×	14.9×	43.2×
2016	37.2×	37.1×	63.5×

Against its peers

Companies in Drug Manufacturers - General nearest CytomX Therapeutics' size, closest first, today.

Company	Price to sales ratio
CTMXCytomX Therapeutics	27.6×
ARVNArvinas	1.5×
PBYIPuma Biotechnology	2.5×
IRWDIronwood Pharmaceuticals	1.5×
ZVRAZevra Therapeutics	4.3×
CRMDCorMedix	1.3×
COLLCollegium Pharmaceutical	0.9×
ABUSArbutus Biopharma	4.6×
AMPHAmphastar Pharmaceuticals	1.5×
NATRNatures Sunshine Products	0.4×
OMEROmeros	n/m
Peer median	1.5×

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on CytomX Therapeutics

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.